AbobotulinumtoxinA, onabotulinumtoxinA and incobotulinumtoxinA were associated with similar efficacy in facial synkinesis within 4 weeks of treatment.
The current single-blind randomized clinical trial included 28 patients treated at a single center in the United States. Eligible participants assessed their own severity of synkinesis using the Synkinesis Assessment Questionnaire at 1, 2 and 4 weeks after treatment.
Data are included for 38 treatments, and six patients enrolled in the study more than once. Fifteen onabotulinumtoxinA, 13 abobotulinumtoxinA and 10 incobotulinumtoxinA courses
Uncategorized